



France officially published list of endocrine disruptors

On October 12, 2023, the French official gazette issued three decrees related to endocrine disrupting substances in products. The decrees require that products and their packaging contain more than 0.1% of endocrine disrupting substances, and the responsible party needs to provide information about endocrine disrupting substances in the products to the public electronically. The decrees come into effect the next day from the date of the official gazette.

In 2020, France issued Decree No. 2020-105 on "Fight Against Waste and the Circular Economy". Article 13-II of the Act requires that anyone who places products or packaging on the market for consumer use containing proven or assumed endocrine disrupting substances that have an impact on food, the environment, and work health by the National Safety Administration must provide relevant information to the public in an open format and electronic format. There are two categories of endocrine disruptors declared by decree:

- Table A and Table A bis: Substances that have been confirmed and speculated to have endocrine disrupting properties (both tables include a total of 128 substances, of which 126 are SVHC substances, and the other two substances are Cholecalciferol (a type of vitamin D) and Mancozeb (a broad-spectrum fungicide for plant protection));
- Table B and Table B bis: Substances suspected to have endocrine disrupting properties (currently there are no substances in both tables).

According to the decree, the responsible party for placing products containing endocrine disrupting substances with concentrations exceeding 0.1% on the market is obliged to disclose this information through an electronic platform open to the public (Scan4Chem).

The content of disclosed information mainly includes:

- ◆ When containing confirmed and speculated endocrine disrupting substances, the statement includes: containing one or more substances with confirmed or inferred endocrine disrupting properties;
- ◆ When containing suspicious endocrine disrupting substances, the statement includes: containing one or more substances with suspicious endocrine disrupting characteristics;
- ◆ The declaration should list the specific substance name and also indicate whether the substance exists in the product or packaging;
- ◆ For substances containing Table A bis (currently Cholecalciferol) and Table B bis (currently not present), special regulations are declared.

Original link: <https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000048193237>

Contact us:

Shenzhen Hongcai testing technology co., LTD. (HCT)

Web: <http://www.hct-test.com/>

Hotline: 400-0066-989 T: (86) 755 8416666

Email: service@hct-test.com

Add: Building B, Tianji Industrial Park, Floor 1&2&3 No.30-9 Laiyin Road,

Xinsheng Community, Longgang Street, Longgang District, Shenzhen,

Guangdong, China

Statement: This publication is only educational and does not replace any legal requirements or applicable rules. Information included in the publication will not be revised. HCT does not guarantee that the content contained in the publication without any errors or will meet any particular performance or quality standards. If there is no consent of HCT in advance, please do not quote or refer any information contained in this publication.